Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On May 15, 2024, CervoMed Inc. (CRVO) announced financial results for the first quarter of 2024 and provided a business update.</li><li>Enrollment is ongoing in the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB).</li><li>We anticipate enrollment completing in the second quarter of 2024 with topline data from the trial expected in the fourth quarter of 2024.</li></ul>

On May 15, 2024, CervoMed Inc. (CRVO) announced financial results for the first quarter of 2024 and provided a business update.Enrollment is ongoing in the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB).We anticipate enrollment completing in the second quarter of 2024 with topline data from the trial expected in the fourth quarter of 2024.

CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24  Topline Data in 4Q24 

United States

Cervomed Inc. operates as a clinical stage biotechnology company. The Company develops and commercializes drug treatments for dementia with lewy bodies, alzheimer's disease, and other central nervous system disorders. CervoMed serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CervoMed (CRVO US)

CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24 Topline Data in 4Q24

On May 15, 2024, CervoMed Inc. (CRVO) announced financial results for the first quarter of 2024 and provided a business update. Enrollment is...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)